A novel therapy for treatment of degenerative spinal conditions

一种治疗退行性脊柱疾病的新疗法

• 批准号: 10024060
• 金额: $ 20.89万
• 依托单位: MICA BIOSYSTEMS LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10024060
• 关键词: novel; therapy; treatment; degenerative; spinal

Low back (LBP) pain and Chronic Low Back Pain (CLBP) represent a common condition linked to musculoskeletal diseases, which affect aged population and represent a major social and economic problem in developed countries. LBP is more common among people aged 40--80 years. The overall number of individuals affected is expected to increase as the population ages. Globally, about 40% of people have LBP at some point in their lives, with estimates as high as 80% of people affected in the developed world. LBP and CLBP in adults doubled in the last decade, continue to increase dramatically in the aging population, with a significant impact on functional ability resulting in significant pain, disability, restriction of activities such as sport, and an inability to work. Economic burden owing to the management of these conditions is significant.Spinal fusion is a surgical procedure to treat these disease conditions and spinal instability. When physiotherapy and conservative approaches fail, the pain and quality of life of patient can be significantly worsened. Fusion involves surgically joining two or more vertebrae through instrumentation and bone grafts, reducing the normal mobility of the spine which may help patients to feel better and may improve their quality of life. The current gold standard treatment uses sources of healthy bone from other regions of the patient, but this procedure holds several drawbacks: increased surgical time, greater costs, donor-site post-operative pain and morbidity, and limited availability of patient's bone especially for long spinal segment fusions.Over the years, donor bone and types of artificial biomaterials including metallic, ceramic, and polymers have been used clinically to improve vertebral fusion, offering mechanical stability. However, they lack the bone forming properties of the patients' own bone. Moreover, in patients suffering from osteoporosis, these implants are problematic to be implanted with sufficient stability. The gold standard graft to accelerate bone fusion currently still remains the commercial sources or autologous bone graft harvested from the hip or collected during the operation with issues of low levels of long term successful outcomes.We have developed an innovative approach which can provide potential solutions for spinal repair with enhanced successful outcomes. Using a patented and novel biomagnetic cell based approach, we can control the way bone forms in the spine enabling precise and increased bone formation for fusion of the spine. This Innovate program will enable us to test the feasibility of our therapy for spinal applications.

下背痛（LBP）和慢性下背痛（CLBP）是与肌肉骨骼疾病相关的常见疾病，影响老年人口，是发达国家的主要社会和经济问题。LBP在40- 80岁的人群中更为常见。随着人口老龄化，预计受影响的总人数将增加。在全球范围内，大约40%的人在一生中的某个时候患有腰痛，估计发达国家受影响的人高达80%。成人LBP和CLBP在过去十年中翻了一番，在老龄化人口中继续急剧增加，对功能能力产生重大影响，导致严重疼痛，残疾，运动等活动受限和无法工作。脊柱融合术是治疗这些疾病和脊柱不稳定的外科手术。当物理治疗和保守方法失败时，患者的疼痛和生活质量可能会显着恶化。融合涉及通过手术器械和骨移植物将两个或多个椎骨连接起来，减少脊柱的正常活动性，这可能有助于患者感觉更好，并可能改善他们的生活质量。目前的金标准治疗使用来自患者其他区域的健康骨骼来源，但这种方法有几个缺点：增加的手术时间、更高的成本、供体部位术后疼痛和发病率，以及患者骨的有限可用性，特别是对于长脊柱节段融合。并且聚合物已经在临床上用于改善椎骨融合，提供机械稳定性。然而，它们缺乏患者自身骨的骨形成特性。此外，在患有骨质疏松症的患者中，这些植入物难以以足够的稳定性植入。目前加速骨融合的金标准移植物仍然是商业来源或从髋关节采集或在手术中收集的自体骨移植物，长期成功率较低。我们开发了一种创新方法，可以为脊柱修复提供潜在的解决方案，提高成功率。使用专利和新颖的基于生物磁性细胞的方法，我们可以控制脊柱中骨形成的方式，从而实现脊柱融合所需的精确和增加的骨形成。该创新计划将使我们能够测试我们的治疗方法在脊柱应用中的可行性。